-
Editorial Team
Posts
Cancer immunotherapy may work better in patients with specific genes
Date:December 15, 2017 Source:Columbia University Medical Center Summary:Investigators have been trying to understand why and have recently found how an individual’s own genes can play...
Dana-Farber Cancer Institute CEO Wants To Tax Biopharma To Pay For The NIH
Dr. Laurie Glimcher, President and CEO of the Dana-Faber Cancer Institute (DFCI), is justifiably concerned that Congress is not providing sufficient funding for the NIH....
NurOwn, Now in Phase 3 Trial, Shows Potential in ALS Patients with Rapid Progression, BrainStorm’s CMO Says in Interview
BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International...
Dpharm 2017 Summary now available
The Conference Forum was delighted to present the 7th annual DPharm: Disruptive Innovations to Advance Clinical Trials conference, with a full day dedicated to Mobile in Clinical Trials on Wednesday...
Join FierceBiotech at the J.P. Morgan Healthcare Conference
Will you be at the J.P. Morgan Healthcare Conference in January? If so, I hope you’ll join us for the FierceBiotech Executive Breakfast, Get Good...